BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985]
URL: https://www.wjgnet.com/1948-5182/full/v25/i33/4985.htm
Number Citing Articles
Dong Hyun Kim, Yu-Min Choi, Junghwa Jang, Bum-Joon Kim. Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: Predominance of the C2(3) clade in South KoreaFrontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1137084
Manas K. Behera, Girish K. Pati, Jimmy Narayan, Debakanta Mishra, Lalit K. Meher, Ayaskant Singh, Kanishka Uthansingh, Manoj K. Sahu. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen–Positive Chronic Hepatitis BJournal of Clinical and Experimental Hepatology 2021; 11(1): 37 doi: 10.1016/j.jceh.2020.05.003